Helping an oncology company with a preclinical project to seek finance and potential acquisition

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...
Learn More

Valuing a cancer immunotherapy asset

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.
Learn More

Valuing multinational pharma company partnerships

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...
Learn More

Supporting a biotech company’s pharma partnerships

Challenge A biotech company needed support with an active partnering process with several major pharma companies.
Learn More

Evaluating a pipeline agreement with a platform tech company

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...
Learn More

Valuation and Deal Support

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...
Learn More

Observer on BoD for private equity investor

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...
Learn More

Cancer immunotherapy consulting

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...
Learn More

Business Development and Partnering Support

Valuations For a biotech company engaged in licensing discussions with a number of major pharmaceutical companies, Alacrita developed rNPV valuations for each program. This 'theoretical' valuation...
Learn More

Antibodies

Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the...
Learn More